



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Pabinafusp alfa

Cat. No.:	HY-P99797
CAS No.:	2140211-48-7
Target:	Transferrin Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice ^[1] .									
IC₅₀ & Target	Transferrin receptor ^[1]									
In Vivo	<p>Pabinafusp alfa (0.1-2 mg/kg; i.v.; once weekly for 36 weeks) dose-dependently prevents neurohistopathological changes and ameliorates neurological defects in a mouse model of MPS II^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mouse model of MPS II^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1 mg/kg, 0.5 mg/kg, and 2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; once weekly for 36 weeks</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently decreases the level of heparan sulfate (HS) in the brain and cerebrospinal fluid (CSF), as well as decreasing the substrate concentrations. Recovered spontaneous alterations in a dose-dependent manner, indicating an impaired working memory prevented.</td> </tr> </table>		Animal Model:	Mouse model of MPS II ^[1]	Dosage:	0.1 mg/kg, 0.5 mg/kg, and 2 mg/kg	Administration:	Intravenous injection; once weekly for 36 weeks	Result:	Dose-dependently decreases the level of heparan sulfate (HS) in the brain and cerebrospinal fluid (CSF), as well as decreasing the substrate concentrations. Recovered spontaneous alterations in a dose-dependent manner, indicating an impaired working memory prevented.
Animal Model:	Mouse model of MPS II ^[1]									
Dosage:	0.1 mg/kg, 0.5 mg/kg, and 2 mg/kg									
Administration:	Intravenous injection; once weekly for 36 weeks									
Result:	Dose-dependently decreases the level of heparan sulfate (HS) in the brain and cerebrospinal fluid (CSF), as well as decreasing the substrate concentrations. Recovered spontaneous alterations in a dose-dependent manner, indicating an impaired working memory prevented.									

REFERENCES

[1]. Morimoto H, et al. Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice. *Mol Ther Methods Clin Dev.* 2022 May 10;25:534-544.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA